Kuros Biosciences Publishes Superior MAXA Study Outcomes in Spine

Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences has announced the peer-reviewed publication of its MAXA Level 1 study in Spine, revealing MagnetOs' superior efficacy over autograft in spinal fusion surgeries. The study, involving 91 patients and 128 segments, demonstrated a 79% fusion rate with MagnetOs, compared to 47% with autograft.

The MAXA study, led by Dr. Moyo C. Kruyt, is a prospective, multi-center, randomized trial. It explores the effectiveness of biphasic calcium phosphate ceramic in posterolateral fusions. Kuros' CEO, Chris Fair, emphasized the company's dedication to evidence-based bone healing technologies.

Full study details, including design and patient demographics, are available on the Spine and Kuros websites. The study underscores Kuros' commitment to advancing spinal fusion treatments for difficult cases.